UnknownNot Applicable

Chemotherapy Induced Neuropathy in Cancer Patients

India124 participantsStarted 2022-11-23

Plain-language summary

The purpose of this prospective study is to perform Nerve conduction test, Vitamin D, Vitamin B12 and NADPH oxidase 4(NOX4) expression to assess severity of chemotherapy induced Peripheral neuropathy (CIPN) in solid cancer (Head and Neck, Breast, Prostate) patients who planned for at least 4 cycle of chemotherapy in different nutrient status level and gene expression.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients receiving chemotherapy for solid cancer * Patient aged\>18years Exclusion Criteria: * Age ≤ 18 years * Pre-existing neuropathy * Patients diagnosed with Psychiatric illness * Patients with pre-existing peripheral neuropathy * Patients taking medication for neuropathy * Long standing diabetes (\>10 years) * Renal and Hepatic disease

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Assessment of different type and severity of Neuropathy in Solid Cancer Patients Undergoing Chemotherapy using Total Neuropathy Score(TNS) and Nerve conduction velocity study

Timeframe: Baseline and after 4th cycle of chemotherapy ( 3weekly cycle) 84 days

NOX4 Gene Expression in Blood of Solid Cancer Patients Undergoing Chemotherapy

Timeframe: at Baseline and after 4th cycle of chemotherapy (3weekly cycle) 84 days

Serum Vitamin D and Homocysteine Levels in Solid Cancer Patients Undergoing Chemotherapy

Timeframe: at baseline and after 4th cycle of chemotherapy ( 3weekly cycle) 84 days

serum catalase and malondialdehyde level in solid cancer patients undergoing chemotherapy

Timeframe: at baseline and after 4th cycle of chemotherapy ( 3weekly cycle= 84 days)

Nerve conduction studies (NCS)

Timeframe: at baseline and after 4th cycle of chemotherapy ( 3weekly cycle= 84 days)

Trial details

NCT IDNCT06491082

SponsorSwami Rama Himalayan University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-08-20

View on ClinicalTrials.gov More Chemotherapy-induced Peripheral Neuropathy trials